Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
395.92
+8.15 (2.10%)
At close: Aug 13, 2025, 4:00 PM
396.00
+0.08 (0.02%)
After-hours: Aug 13, 2025, 7:58 PM EDT
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
8.92
Revenue / Employee
$1,871,934
Employees
6,100
Market Cap
101.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VRTX News
- 1 day ago - Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet - Seeking Alpha
- 2 days ago - Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade) - Seeking Alpha
- 8 days ago - Weakness In Vertex Stock Seen As Buying Opportunity - Benzinga
- 8 days ago - These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Benzinga
- 8 days ago - Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug - Investopedia
- 8 days ago - Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 9 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Vertex tops estimates on cystic fibrosis treatment strength, new products - Reuters